DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tucatinib
Tucatinib
Cogent Biosciences Announces Creation of Cogent Research Team
Prior Authorization Oncology – Tukysa™ (Tucatinib Tablets)
Insights from Drug Discovery Life Cycle Management in Pharmaceutical Industry: a Case-Study B
Rxoutlook® 1St Quarter 2019
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
Tucatinib (Tukysa™) EOCCO POLICY
Tucatinib Combined with Ado-Trastuzumab Emtansine In
(NCCN) Breast Cancer Clinical Practice Guidelines
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
Targeting Transcription of MCL-1 Sensitizes HER2-Amplified Breast Cancers to HER2 Inhibitors
Full Prescribing Information [FDA]
TUKYSA (Tucatinib) RATIONALE for INCLUSION in PA PROGRAM
Oncology Approvals in 2020: a Year of Firsts in the Midst of a Pandemic
Potential Exploration of Recent FDA-Approved Anticancer Drugs Against Models of SARS-Cov-2’S Main Protease and Spike Glycoprotein: a Computational Study
Drugs with Special Ordering Procedures (SAP Chart)
Trastuzumab Deruxtecan: a Quantum Leap in HER2-Positive Breast Cancer
Using the Structural Kinome to Systematize Kinase Drug Discovery
TUKYSA, INN-Tucatinib
Top View
Evidence Dossier
Oncology Center of Excellence 2020 Annual Report
Therapeutic Advances in Oncology
Specialty Pipeline MONTHLY UPDATE
January 2021 L.A. Care Covered Formulary
Adult Antiemetic Management of Chemotherapy-Induced Nausea
CY 2020 CDER New Molecular Entity (NME) Drug & Original BLA Calendar Year Approvals As of Decemeber 31, 2020
Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
Drug Information Center Highlights of FDA Activities – 4/1/2020
Present and Emerging Treatment Options in Her2/Neu Overexpressing Metastatic Breast Cancer
Oncology Agents Policy #: Rx.01.67
Combining CD47 Blockade with Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance
Comparative Analysis of Drug Response and Gene Profiling Of
RANK Signaling Increases After Anti-HER2 Therapy Contributing To
In Vitro and Ex Vivo Anti‑Tumor Effect and Mechanism of Tucatinib in Leukemia Stem Cells and ABCG2‑Overexpressing Leukemia Cells
List Item Applications for New Human
Tyrosine Kinase Inhibitors - Oral
2020 Pharmacy Drug Guide High Value Plan 2021 Aetna Pharmacy Drug Guide
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
CVS Caremark® Value Formulary Effective As of 07/01/2021
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
New Prescription and OTC Medication Update
Treatment and Side Effects
Colon Cancer Data Key As Pfizer Buys Array
(CHMP) Agenda for the Meeting on 12-15 October 2020
HER2 Splice Variants in Breast Cancer: Investigating Their Impact on Diagnosis and Treatment Outcomes
Precision Oncology Drug Approvals in 2020 - New Drugs and Expanded Indications
Tucatinib (Tukysa®) with Trastuzumab and Capecitabine for the Treatment of HER2-Positive Locally Advanced Or Metastatic Breast Cancer
213411Orig1s000
Publication Agenda CHMP 07-10 December 2020
Risk Assessment and Risk Mitigation Review(S)
Tyrosine Kinase Receptors in Oncology
Mct First Disclosures